Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

ASTELLAS PHARMA A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Bankruptcy risk for industry   1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1%   Bankruptcy risk   0.7% 2.0% 1.9% 1.7% 2.0% 2.0% 8.0% 7.8%   Credit score (0-100)   96 71 71 71 68 67 31 31   Credit rating   AA A A A A A BB BB   Credit limit (mEUR)   6.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mEUR)  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales   183 187 160 180 181 187 187 187   Gross profit   25.0 23.8 24.1 26.2 23.1 20.9 0.0 0.0   EBITDA   6.6 5.5 6.4 9.0 5.2 6.0 0.0 0.0   EBIT   6.5 5.5 6.4 9.0 5.1 5.9 0.0 0.0   Pre-tax profit (PTP)   6.2 2.0 5.9 6.7 2.9 6.0 0.0 0.0   Net earnings   4.7 2.0 5.9 6.7 2.1 4.5 0.0 0.0   Pre-tax profit without non-rec. items   6.2 5.5 6.4 9.0 2.9 6.0 0.0 0.0     See the entire income statement 1.0 Balance sheet (mEUR)  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Tangible assets total   0.3 0.0 0.0 0.0 0.2 0.2 0.0 0.0   Shareholders equity total   56.2 53.6 59.4 58.2 35.3 24.7 14.6 14.6   Interest-bearing liabilities   29.4 0.0 0.0 0.0 29.9 34.9 0.0 0.0   Balance sheet total (assets)   130 127 145 346 112 101 14.6 14.6   Net Debt   26.6 0.0 0.0 0.0 16.0 25.5 -14.6 -14.6     See the entire balance sheet 1.0 Volume  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales   183 187 160 180 181 187 187 187   Net sales growth   15.7% 2.4% -14.2% 12.1% 0.5% 3.3% 0.0% 0.0%   Gross profit   25.0 23.8 24.1 26.2 23.1 20.9 0.0 0.0   Gross profit growth   22.1% -4.7% 1.1% 8.6% -11.7% -9.6% -100.0% 0.0%   Employees   115 0 0 0 103 97 0 0   Employee growth %   0.9% -100.0% 0.0% 0.0% 0.0% -5.8% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   130 127 145 346 112 101 15 15   Balance sheet change%   25.6% -2.0% 14.5% 137.6% -67.6% -10.1% -85.5% 0.0%   Added value   6.6 5.5 6.4 9.0 5.1 6.0 0.0 0.0   Added value %   3.6% 2.9% 4.0% 5.0% 2.8% 3.2% 0.0% 0.0%   Investments   -0 -0 0 0 0 -0 -0 0   Net sales trend   2.0 3.0 -1.0 1.0 2.0 3.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1.0 Profitability  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A EBITDA %   3.6% 2.9% 4.0% 5.0% 2.9% 3.2% 0.0% 0.0%   EBIT %   3.6% 2.9% 4.0% 5.0% 2.8% 3.2% 0.0% 0.0%   EBIT to gross profit (%)   26.0% 23.0% 26.6% 34.5% 22.1% 28.4% 0.0% 0.0%   Net Earnings %   2.6% 1.1% 3.7% 3.7% 1.2% 2.4% 0.0% 0.0%   Profit before depreciation and extraordinary items %   2.7% 1.1% 3.7% 3.7% 1.2% 2.4% 0.0% 0.0%   Pre tax profit less extraordinaries %   3.4% 2.9% 4.0% 5.0% 1.6% 3.2% 0.0% 0.0%   ROA %   6.9% 4.3% 4.7% 3.7% 5.2% 16.1% 0.0% 0.0%   ROI %   9.5% 5.2% 4.7% 3.7% 5.8% 27.5% 0.0% 0.0%   ROE %   8.6% 3.7% 10.4% 11.4% 4.4% 14.9% 0.0% 0.0%   1.0 Solidity  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Equity ratio %   43.4% 100.0% 100.0% 100.0% 31.5% 24.5% 100.0% 100.0%   Relative indebtedness %   40.2% 0.0% 0.0% 0.0% 42.4% 40.7% 0.0% 0.0%   Relative net indebtedness %   38.7% 0.0% 0.0% 0.0% 34.7% 35.7% -7.8% -7.8%   Net int. bear. debt to EBITDA, %   402.1% 0.0% 0.0% 0.0% 306.2% 425.4% 0.0% 0.0%   Gearing %   52.3% 0.0% 0.0% 0.0% 84.7% 141.3% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   6.1% 0.0% 0.0% 0.0% 60.9% 34.5% 0.0% 0.0%   1.0 Liquidity  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Quick Ratio   1.2 0.0 0.0 0.0 1.5 1.3 0.0 0.0   Current Ratio   1.8 0.0 0.0 0.0 1.5 1.3 0.0 0.0   Cash and cash equivalent   2.8 0.0 0.0 0.0 13.9 9.4 0.0 0.0   1.0 Capital use efficiency  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Trade debtors turnover (days)   77.8 0.0 0.0 0.0 95.9 85.2 0.0 0.0   Trade creditors turnover (days)   17.5 0.0 0.0 0.0 133.9 30.3 0.0 0.0   Current assets / Net sales %   70.5% 0.0% 0.0% 0.0% 61.8% 53.8% 7.8% 7.8%   Net working capital   55.4 0.0 0.0 0.0 35.0 24.4 0.0 0.0   Net working capital %   30.4% 0.0% 0.0% 0.0% 19.4% 13.1% 0.0% 0.0%   1.0 Employee efficiency  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales / employee   2 0 0 0 2 2 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0